Navigation Links
New Phase IV Clinical Study Indicates LidoSite Provides,Rheumatology Patients Superior Pain Relief

FAIR LAWN, N.J.--(BUSINESS WIRE)--Mar 19, 2007 - Vyteris Holdings (Nevada), Inc. (OTCBB: VYHN), today announced results from a new phase IV "Open Label" clinical study demonstrating that LidoSite, the first FDA approved active patch for dermal analgesia, provided better pain relief to more than 73 percent of patients receiving injections of hyaluronic acid during treatment for osteoarthritis than usual topical analgesics.

"Treatment can be very painful, requiring multiple injections into sensitive joints, with many patients having a difficult time with this pain, leading some to avoid regular treatment," said Dr. Evan Liebowitz, a rheumatologist affiliated with Prospect Medical Office in Midland Park, NJ and Valley Hospital in Ridgewood, NJ. "Patients who avoid regular treatments for rheumatoid arthritis and osteoarthritis risk further loss of articular cartilage in the knee."

The study, involving six study sites and 14 physicians, followed 63 patients over the course of two routine injections of hyaluronic acid for the treatment of osteoarthritis.

During the first treatment, patients either received no local anesthesia or an alternate local anesthesia prior to cannulation or needle puncture. During the second treatment, patients received the LidoSite system, comprised of the LidoSite Patch and the LidoSite Controller. In the study more than 73 percent preferred LidoSite to the treatment used during their first visit. Additionally, the majority of rheumatology physicians surveyed were satisfied with LidoSite, compared to other available treatment options, such as ethyl chloride, lidocaine injections or fluormethane spray.

"This initial study demonstrates the acceptability among patients and rheumatologists for using LidoSite as an effective treatment regime for needle pain for the multiple injections arthritis requires, as well as its potential availability in the doctor's office setting."
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
3. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
7. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
8. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
9. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
10. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
11. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
Post Your Comments:
(Date:3/2/2015)... SOUTH SAN FRANCISCO, Calif. , March 2, ... therapeutics for the treatment of cancer, today announced ... comprised of leading researchers and clinicians in the ... The new advisory boards will ... its wholly owned pipeline of precision immunotherapies and ...
(Date:3/2/2015)... , March 2, 2015   Mast ... biopharmaceutical company, today announced preliminary findings from a ... a model of chronic, stable heart failure produced ... study was to examine the effects of repeat ... systolic and diastolic function. Consistent ...
(Date:3/2/2015)... 2015  Delcath Systems, Inc. (NASDAQ: DCTH ... on oncology with an emphasis on the treatment of ... will participate in the upcoming 27 th Annual ... the Ritz Carlton Laguna Niguel in Dana ... MSN, CRNP, Delcath,s interim President and Chief Executive Officer, ...
Breaking Medicine Technology:CytomX Expands Scientific and Clinical Advisory Boards with Leading Experts in Cancer Immunotherapy and Antibody Drug Conjugates 2CytomX Expands Scientific and Clinical Advisory Boards with Leading Experts in Cancer Immunotherapy and Antibody Drug Conjugates 3Mast Announces Results From Nonclinical Study Investigating Repeat Treatment With Vepoloxamer In Advanced Heart Failure 2Mast Announces Results From Nonclinical Study Investigating Repeat Treatment With Vepoloxamer In Advanced Heart Failure 3Mast Announces Results From Nonclinical Study Investigating Repeat Treatment With Vepoloxamer In Advanced Heart Failure 4Mast Announces Results From Nonclinical Study Investigating Repeat Treatment With Vepoloxamer In Advanced Heart Failure 5Mast Announces Results From Nonclinical Study Investigating Repeat Treatment With Vepoloxamer In Advanced Heart Failure 6Delcath To Present At The 27th Annual Roth Conference 2Delcath To Present At The 27th Annual Roth Conference 3
... The Epilepsy Foundation recently announced findings that show ... a consistent drug therapy, have a greater chance of ... their medications are switched from one version of an ... brand-to-generic, generic-to-brand or generic-to-generic. See video from the Epilepsy ...
... Findings Reinforce March of Dimes Message: Start Taking a ... 11 Women who take folic acid supplements for ... cut their risk of having a premature baby by ... online journal, PLOS Medicine.The study links pre-conceptional folate supplementation ...
Cached Medicine Technology:VIDEO from Medialink and the Epilepsy Foundation: New Study Suggests Different Versions of the Same Epilepsy Medication Can Be Harmful 2Taking Folic Acid for a Year Before Pregnancy May Reduce Risk of Preterm Birth 2
(Date:3/2/2015)... 02, 2015 LegitScript, LLC, ... certification programs, including those for Internet pharmacy ... safety and classification, has launched a certification ... The new program, called iCareRx , ... regarding the identity of the owner/operator of ...
(Date:3/2/2015)... 02, 2015 Regulatory Compliance Associates® ... quality, regulatory and technical consulting, announces Mr. Seyed ... Officer. , Before joining RCA, Mr. Khorashahi ... teams in all aspects of developing safety-critical medical ... Covidien (Medtronic), Regulatory Compliance Associates Inc., Baxter Healthcare, ...
(Date:3/2/2015)... 02, 2015 The Alliance for Bangladesh ... expert Mark Chubb to serve as chief safety officer. ... and training in Bangladesh and guide remediation efforts in ... “Mark will ensure that the Alliance continues to bring ... for Bangladesh garment workers,” said Alliance Independent Chair Ellen ...
(Date:3/2/2015)... 2015 Final Cut Pro X ... 2 from Pixel Film Studios. , “The TranStatic Volume 2 ... said Christina Austin, CEO of Pixel Film Studios. “TranStatic Volume ... Cut Pro X editors toolbox.” , With TranStatic Volume 2 ... media altering static scrambling effects from Pixel Film Studios. Users ...
(Date:3/1/2015)... As residents and business owners in ... and Carita Weaver, believe in supporting local organizations ... Southlake Chamber of Commerce, Carroll Independent School District ... a website for Southlake mayoral candidate Laura Hill: ... for Hill’s campaign, the website combines images, videos ...
Breaking Medicine News(10 mins):Health News:LegitScript Launches Certification Program for Internet Eyeglass Sellers 2Health News:Regulatory Compliance Associates® Inc. Welcomes Seyed Khorashahi as Chief Operating Officer 2Health News:Alliance for Bangladesh Worker Safety Names New Chief Safety Officer 2Health News:Pixel Film Studios released the TranStatic Volume 2 plugin for Final Cut Pro X today 2Health News:Website Launched for Southlake, Texas Mayoral Candidate Laura Hill 2
... older women with breast cancer lag behind younger women diagnosed ... missing out on improvements in treatment and detection, according to ... Center. The study, published in the Journal of ... whether the improvements made in breast cancer outcomes over the ...
... 2011) AMRI (NASDAQ: AMRI) announced today that, as ... and Company, it anticipates hiring more than 40 synthetic ... Lilly,s drug discovery programs. The chemists will work onsite ... support the medicinal chemistry department. This collaboration will ...
... Jenifer Goodwin HealthDay Reporter , MONDAY, Nov. ... child with autism or with a milder form of ... only by the child,s symptoms, but by where the ... found wide variability at autism centers across the nation ...
... CA The University of California, Santa Barbara ... Grand Challenges Explorations, an initiative created by the ... worldwide to test unorthodox ideas that address persistent ... Amr El Abbadi in the Computer Science Department ...
... The Lymphoma Division of the John Theurer Cancer Center at ... groups "Hope for Lymphoma" and "Our MCL Family," will host ... from 8:30am 3:45pm. The event is open to ... patients and their caregivers coping with this challenging diagnosis. ...
... HealthDay Reporter , SUNDAY, Nov. 6 (HealthDay News) -- ... the holiday season for some. For others, those airborne ... and sneezing to asthma attacks. Allergists say as ... complaints from their patients about reactions to them. ...
Cached Medicine News:Health News:UT MD Anderson study finds advances in breast cancer don't extend to older women 2Health News:UT MD Anderson study finds advances in breast cancer don't extend to older women 3Health News:Where a Child Is Tested May Affect Autism Diagnosis 2Health News:Where a Child Is Tested May Affect Autism Diagnosis 3Health News:UC Santa Barbara receives Grand Challenges Explorations funding 2Health News:UC Santa Barbara receives Grand Challenges Explorations funding 3Health News:John Theurer Cancer Center to host inaugural Mantle Cell Lymphoma Symposium 2Health News:John Theurer Cancer Center to host inaugural Mantle Cell Lymphoma Symposium 3Health News:Air Fresheners, Scented Candles May Spur Allergic Reactions 2Health News:Air Fresheners, Scented Candles May Spur Allergic Reactions 3
Portex® Blue Line® cuffed endotracheal tubes come in a wide selection of sizes, each with a standard 15 mm ISO connector., ,Portex® Blue Line® endotracheal tubes are recognized world...
Ruschelit® PVC. Murphy eye-nasoral. X-ray opaque line. Graduated. Single use. Sterile...
Ruschelit® PVC. Magill tip - nasoral. X-ray opaque line. Graduated. Single use. Sterile...
... Tube with stylet inside. Sterile, Latex ... Rusch endotracheal tube with a preloaded ... saving you time and storage space. ... easy identification and has a stopper ...
Medicine Products: